Characteristics, management, and outcome for patients with treatment-emergent AICs
| Patient no. . | AIC type . | Age (y) . | Sex . | IGHV . | FISH . | TP53 . | No. of previous therapies . | Time of occurrence . | Management . | AIC outcome . | Time receiving drug . | Best CLL response . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ibrutinib, total 5 (1%) of 506, AIHA 4 (80%) of 5, ITP 1 (20%) of 5 . | ||||||||||||
| 1 | AIHA | 82 | F | NA | del(17p) | NA | 1 | 3 mo | Ibrutinib dose temporarily reduced | Resolved | 24 mo | PR |
| 2 | AIHA | 77 | M | UM | del(17p) | WT | 2 | 6 mo | Steroids added | Resolved | 20 mo | PR |
| 3 | AIHA | 70 | M | UM | del(11q) | WT | 5 | 1 wk | Ibrutinib temporarily suspended, steroids added, ibrutinib restarted at reduced dose | Resolved | 47 mo | PR |
| 4 | ITP | 61 | M | UM | del(17p) | WT | 0 | 1 mo | Ibrutinib temporarily suspended; steroids, IVIG, and rituximab added; ibrutinib restarted at full dose | Resolved | >22 mo | PR |
| 5 | AIHA | 74 | M | UM | del(17p) | MUT | 1 | 29 mo | Ibrutinib interrupted (concomitant CLL progression), steroids added | Controlled | 29 mo | PR |
| Patient no. . | AIC type . | Age (y) . | Sex . | IGHV . | FISH . | TP53 . | No. of previous therapies . | Time of occurrence . | Management . | AIC outcome . | Time receiving drug . | Best CLL response . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ibrutinib, total 5 (1%) of 506, AIHA 4 (80%) of 5, ITP 1 (20%) of 5 . | ||||||||||||
| 1 | AIHA | 82 | F | NA | del(17p) | NA | 1 | 3 mo | Ibrutinib dose temporarily reduced | Resolved | 24 mo | PR |
| 2 | AIHA | 77 | M | UM | del(17p) | WT | 2 | 6 mo | Steroids added | Resolved | 20 mo | PR |
| 3 | AIHA | 70 | M | UM | del(11q) | WT | 5 | 1 wk | Ibrutinib temporarily suspended, steroids added, ibrutinib restarted at reduced dose | Resolved | 47 mo | PR |
| 4 | ITP | 61 | M | UM | del(17p) | WT | 0 | 1 mo | Ibrutinib temporarily suspended; steroids, IVIG, and rituximab added; ibrutinib restarted at full dose | Resolved | >22 mo | PR |
| 5 | AIHA | 74 | M | UM | del(17p) | MUT | 1 | 29 mo | Ibrutinib interrupted (concomitant CLL progression), steroids added | Controlled | 29 mo | PR |
| Idelalisib, total 1 (0.9%) of 114, AIHA 1 (100%) of 1 . | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 | AIHA | 54 | M | UM | del(11q) | NA | 4 | 25 mo | Idelalisib dose temporarily reduced, steroids added | Controlled | 26 mo | PR |
| Idelalisib, total 1 (0.9%) of 114, AIHA 1 (100%) of 1 . | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 | AIHA | 54 | M | UM | del(11q) | NA | 4 | 25 mo | Idelalisib dose temporarily reduced, steroids added | Controlled | 26 mo | PR |
| Venetoclax, total 6 (7%) of 91, AIHA 4 (67%) of 6, ITP 2 (33%) of 6 . | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7 | AIHA | 79 | M | UM | del(17p) | MUT | 8 | 10 mo | Steroids added | Resolved | >32 mo | PR |
| 8 | AIHA | 58 | M | UM | del(13q) | MUT | 2 | 5 mo | Steroids added | Controlled | 12 mo | PR |
| 9 | ITP | 73 | M | NA | del(17p) | NA | 1 | 5 mo | Venetoclax suspended, steroids and IVIG added | Active | 6 mo | NA |
| 10 | ITP | 58 | M | UM | del(17p) | MUT | 3 | 15 mo | Steroids added | Resolved | >21 mo | PR |
| 11 | AIHA | 70 | M | UM | Negative | MUT | 3 | 3 mo | Venetoclax temporarily suspended, steroids and rituximab added | Controlled | >13 mo | SD |
| 12 | AIHA | 50 | M | NA | NA | MUT | 2 | 3 mo | Rituximab added | Active | 4 mo | SD |
| Venetoclax, total 6 (7%) of 91, AIHA 4 (67%) of 6, ITP 2 (33%) of 6 . | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7 | AIHA | 79 | M | UM | del(17p) | MUT | 8 | 10 mo | Steroids added | Resolved | >32 mo | PR |
| 8 | AIHA | 58 | M | UM | del(13q) | MUT | 2 | 5 mo | Steroids added | Controlled | 12 mo | PR |
| 9 | ITP | 73 | M | NA | del(17p) | NA | 1 | 5 mo | Venetoclax suspended, steroids and IVIG added | Active | 6 mo | NA |
| 10 | ITP | 58 | M | UM | del(17p) | MUT | 3 | 15 mo | Steroids added | Resolved | >21 mo | PR |
| 11 | AIHA | 70 | M | UM | Negative | MUT | 3 | 3 mo | Venetoclax temporarily suspended, steroids and rituximab added | Controlled | >13 mo | SD |
| 12 | AIHA | 50 | M | NA | NA | MUT | 2 | 3 mo | Rituximab added | Active | 4 mo | SD |
F, female; M, male; MUT, mutated; NA, not available; SD, stable disease; UM, unmutated; WT, wild type.